Monte Rosa Therapeutics: Novartis starts Phase 2 study; Monte Rosa to receive $50 million
Monte Rosa Therapeutics said its partner Novartis has started a Phase 2 clinical study of MRT-6160 (DDY391) in people with Sjögren's disease, triggering a $50 million milestone payment to Monte Rosa. The payment is tied to the first patient visit, and the company is eligible for up to $2.1 billion in development, regulatory, and sales milestones under the Novartis agreement. The filing does not report revenue, earnings, or guidance.
Key points
- Novartis initiated a Phase 2a/b study of MRT-6160 (DDY391) in participants with Sjögren's disease; the study is identified as NCT07737743 on ClinicalTrials.gov
- Monte Rosa will receive a $50 million milestone payment from Novartis in connection with the first patient visit
- Monte Rosa is eligible for up to $2.1 billion in development, regulatory, and sales milestones, plus additional Phase 2 study initiation milestones
- Monte Rosa will co-fund any Phase 3 development and share 30% of U.S. manufacturing and commercialization profits and losses for MRT-6160
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 08, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.